Annual EBITDA
-$6.28 M
+$5.96 M+48.68%
31 December 2022
Summary:
Nymox Pharmaceutical annual earnings before interest, taxes, depreciation & amortization is currently -$6.28 million, with the most recent change of +$5.96 million (+48.68%) on 31 December 2022. During the last 3 years, it has risen by +$5.14 million (+45.02%).NYMX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.33 M
-$3.19 M-171.06%
31 March 2023
Summary:
Nymox Pharmaceutical quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.33 million, with the most recent change of -$3.19 million (-171.06%) on 31 March 2023.NYMX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$2.59 M
+$3.69 M+58.73%
31 March 2023
Summary:
Nymox Pharmaceutical TTM earnings before interest, taxes, depreciation & amortization is currently -$2.59 million, with the most recent change of +$3.69 million (+58.73%) on 31 March 2023.NYMX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NYMX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | +45.0% | +59.0% | +77.3% |
| 5 y5 years | +40.6% | +45.7% | +79.8% |
NYMX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | ||||||
| 5 y | 5 years | ||||||
| alltime | all time | +123.9% | -171.1% | -2685.2% |
Nymox Pharmaceutical EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$1.33 M(-171.1%) | -$2.59 M(-58.7%) |
| Dec 2022 | -$6.28 M(-48.7%) | $1.87 M(-231.4%) | -$6.28 M(-42.2%) |
| Sept 2022 | - | -$1.42 M(-17.1%) | -$10.87 M(-14.3%) |
| June 2022 | - | -$1.71 M(-65.8%) | -$12.69 M(-14.8%) |
| Mar 2022 | - | -$5.02 M(+84.2%) | -$14.89 M(+21.7%) |
| Dec 2021 | -$12.24 M(+7.1%) | -$2.72 M(-15.8%) | -$12.24 M(+7.2%) |
| Sept 2021 | - | -$3.23 M(-17.5%) | -$11.42 M(-7.0%) |
| June 2021 | - | -$3.92 M(+65.9%) | -$12.27 M(+9.5%) |
| Mar 2021 | - | -$2.36 M(+24.5%) | -$11.21 M(-1.5%) |
| Dec 2020 | -$11.43 M(-9.0%) | -$1.90 M(-53.6%) | -$11.39 M(-4.4%) |
| Sept 2020 | - | -$4.09 M(+42.9%) | -$11.90 M(+16.0%) |
| June 2020 | - | -$2.86 M(+12.8%) | -$10.26 M(-18.2%) |
| Mar 2020 | - | -$2.54 M(+4.9%) | -$12.54 M(-0.3%) |
| Dec 2019 | -$12.56 M(+18.8%) | -$2.42 M(-1.1%) | -$12.57 M(-2.1%) |
| Sept 2019 | - | -$2.44 M(-52.4%) | -$12.84 M(-2.8%) |
| June 2019 | - | -$5.14 M(+99.4%) | -$13.21 M(+25.9%) |
| Mar 2019 | - | -$2.58 M(-4.1%) | -$10.49 M(-0.8%) |
| Dec 2018 | -$10.57 M(-20.0%) | -$2.69 M(-4.4%) | -$10.57 M(-5.5%) |
| Sept 2018 | - | -$2.81 M(+16.1%) | -$11.19 M(-13.6%) |
| June 2018 | - | -$2.42 M(-9.0%) | -$12.94 M(-1.3%) |
| Mar 2018 | - | -$2.66 M(-19.4%) | -$13.12 M(-0.8%) |
| Dec 2017 | -$13.22 M(+2.7%) | -$3.30 M(-27.8%) | -$13.22 M(+4.0%) |
| Sept 2017 | - | -$4.57 M(+75.9%) | -$12.72 M(+13.6%) |
| June 2017 | - | -$2.60 M(-6.0%) | -$11.20 M(-9.5%) |
| Mar 2017 | - | -$2.76 M(-1.0%) | -$12.37 M(-3.9%) |
| Dec 2016 | -$12.87 M(-27.3%) | -$2.79 M(-8.4%) | -$12.87 M(-9.0%) |
| Sept 2016 | - | -$3.05 M(-19.2%) | -$14.15 M(-32.9%) |
| June 2016 | - | -$3.77 M(+15.4%) | -$21.08 M(-6.7%) |
| Mar 2016 | - | -$3.27 M(-19.6%) | -$22.60 M(+27.7%) |
| Dec 2015 | -$17.70 M(+285.0%) | -$4.06 M(-59.3%) | -$17.70 M(+24.8%) |
| Sept 2015 | - | -$9.98 M(+88.5%) | -$14.18 M(+189.5%) |
| June 2015 | - | -$5.29 M(-424.5%) | -$4.90 M(+1185.5%) |
| Mar 2015 | - | $1.63 M(-401.2%) | -$381.00 K(-91.7%) |
| Dec 2014 | -$4.60 M(-6.0%) | -$541.50 K(-22.2%) | -$4.60 M(-14.6%) |
| Sept 2014 | - | -$695.60 K(-10.2%) | -$5.38 M(-5.4%) |
| June 2014 | - | -$774.70 K(-70.0%) | -$5.69 M(-10.9%) |
| Mar 2014 | - | -$2.59 M(+94.9%) | -$6.38 M(+30.5%) |
| Dec 2013 | -$4.89 M(-35.7%) | -$1.33 M(+32.7%) | -$4.89 M(-23.5%) |
| Sept 2013 | - | -$999.90 K(-32.1%) | -$6.39 M(-3.5%) |
| June 2013 | - | -$1.47 M(+34.7%) | -$6.62 M(-3.5%) |
| Mar 2013 | - | -$1.09 M(-61.4%) | -$6.86 M(-9.8%) |
| Dec 2012 | -$7.61 M(-21.0%) | -$2.83 M(+129.9%) | -$7.60 M(+18.3%) |
| Sept 2012 | - | -$1.23 M(-28.1%) | -$6.43 M(-5.6%) |
| June 2012 | - | -$1.71 M(-6.7%) | -$6.81 M(-3.1%) |
| Mar 2012 | - | -$1.83 M(+11.0%) | -$7.02 M(-26.8%) |
| Dec 2011 | -$9.63 M(+47.4%) | -$1.65 M(+2.8%) | -$9.59 M(-4.0%) |
| Sept 2011 | - | -$1.61 M(-16.6%) | -$9.99 M(-0.4%) |
| June 2011 | - | -$1.93 M(-56.3%) | -$10.03 M(+2.9%) |
| Mar 2011 | - | -$4.41 M(+114.6%) | -$9.75 M(+49.6%) |
| Dec 2010 | -$6.53 M | -$2.05 M(+24.8%) | -$6.52 M(+9.6%) |
| Sept 2010 | - | -$1.65 M(0.0%) | -$5.95 M(+6.1%) |
| June 2010 | - | -$1.65 M(+40.0%) | -$5.61 M(+9.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2010 | - | -$1.18 M(-20.8%) | -$5.13 M(+4.7%) |
| Dec 2009 | -$4.90 M(+11.3%) | -$1.48 M(+13.8%) | -$4.90 M(+9.3%) |
| Sept 2009 | - | -$1.30 M(+12.3%) | -$4.48 M(+1.9%) |
| June 2009 | - | -$1.16 M(+22.8%) | -$4.40 M(+3.6%) |
| Mar 2009 | - | -$946.10 K(-11.4%) | -$4.25 M(-3.5%) |
| Dec 2008 | -$4.40 M(-7.5%) | -$1.07 M(-12.6%) | -$4.40 M(-2.2%) |
| Sept 2008 | - | -$1.22 M(+21.0%) | -$4.50 M(-0.8%) |
| June 2008 | - | -$1.01 M(-8.3%) | -$4.53 M(-6.6%) |
| Mar 2008 | - | -$1.10 M(-5.6%) | -$4.85 M(+2.1%) |
| Dec 2007 | -$4.76 M(+9.0%) | -$1.17 M(-7.3%) | -$4.75 M(+1.7%) |
| Sept 2007 | - | -$1.26 M(-5.3%) | -$4.67 M(+3.2%) |
| June 2007 | - | -$1.33 M(+32.5%) | -$4.53 M(+2.3%) |
| Mar 2007 | - | -$1.00 M(-7.7%) | -$4.43 M(+1.4%) |
| Dec 2006 | -$4.37 M(+40.8%) | -$1.09 M(-2.5%) | -$4.37 M(+9.9%) |
| Sept 2006 | - | -$1.11 M(-9.3%) | -$3.97 M(+7.4%) |
| June 2006 | - | -$1.23 M(+30.3%) | -$3.70 M(+15.5%) |
| Mar 2006 | - | -$941.80 K(+36.4%) | -$3.20 M(+3.2%) |
| Dec 2005 | -$3.10 M(-2.5%) | -$690.30 K(-17.7%) | -$3.10 M(-1.4%) |
| Sept 2005 | - | -$839.00 K(+14.7%) | -$3.15 M(+9.3%) |
| June 2005 | - | -$731.30 K(-13.3%) | -$2.88 M(-9.4%) |
| Mar 2005 | - | -$843.20 K(+15.0%) | -$3.18 M(-0.3%) |
| Dec 2004 | -$3.18 M(-18.6%) | -$733.20 K(+28.4%) | -$3.18 M(-15.8%) |
| Sept 2004 | - | -$571.00 K(-44.5%) | -$3.78 M(-4.2%) |
| June 2004 | - | -$1.03 M(+20.8%) | -$3.95 M(+0.2%) |
| Mar 2004 | - | -$851.50 K(-36.1%) | -$3.94 M(+0.7%) |
| Dec 2003 | -$3.91 M(+29.8%) | -$1.33 M(+81.0%) | -$3.91 M(+16.6%) |
| Sept 2003 | - | -$736.40 K(-27.8%) | -$3.36 M(+1.1%) |
| June 2003 | - | -$1.02 M(+23.5%) | -$3.32 M(+8.0%) |
| Mar 2003 | - | -$825.80 K(+6.5%) | -$3.07 M(+2.0%) |
| Dec 2002 | -$3.01 M(+7.3%) | -$775.40 K(+11.0%) | -$3.01 M(-8.1%) |
| Sept 2002 | - | -$698.50 K(-9.6%) | -$3.28 M(+3.1%) |
| June 2002 | - | -$772.50 K(+0.8%) | -$3.18 M(+3.9%) |
| Mar 2002 | - | -$766.30 K(-26.3%) | -$3.06 M(+9.2%) |
| Dec 2001 | -$2.81 M(-24.2%) | -$1.04 M(+73.3%) | -$2.80 M(+8.7%) |
| Sept 2001 | - | -$599.80 K(-8.4%) | -$2.58 M(-9.0%) |
| June 2001 | - | -$654.60 K(+28.9%) | -$2.84 M(-17.1%) |
| Mar 2001 | - | -$508.00 K(-37.8%) | -$3.42 M(-7.4%) |
| Dec 2000 | -$3.70 M(+13.7%) | -$816.30 K(-4.7%) | -$3.70 M(-3.7%) |
| Sept 2000 | - | -$856.30 K(-31.0%) | -$3.84 M(-1.1%) |
| June 2000 | - | -$1.24 M(+58.4%) | -$3.88 M(+27.8%) |
| Mar 2000 | - | -$783.30 K(-18.2%) | -$3.04 M(-7.8%) |
| Dec 1999 | -$3.26 M(-30.4%) | -$957.00 K(+6.5%) | -$3.30 M(-8.7%) |
| Sept 1999 | - | -$898.80 K(+125.8%) | -$3.61 M(-7.8%) |
| June 1999 | - | -$398.00 K(-61.8%) | -$3.91 M(-13.3%) |
| Mar 1999 | - | -$1.04 M(-18.1%) | -$4.52 M(-1.3%) |
| Dec 1998 | -$4.68 M(+38.5%) | -$1.27 M(+5.7%) | -$4.57 M(+14.8%) |
| Sept 1998 | - | -$1.20 M(+20.2%) | -$3.98 M(+8.2%) |
| June 1998 | - | -$1.00 M(-9.0%) | -$3.68 M(+5.8%) |
| Mar 1998 | - | -$1.10 M(+61.6%) | -$3.48 M(+52.6%) |
| Dec 1997 | -$3.38 M | -$680.40 K(-24.4%) | -$2.28 M(+42.5%) |
| Sept 1997 | - | -$899.80 K(+12.5%) | -$1.60 M(+128.6%) |
| June 1997 | - | -$799.80 K(-897.4%) | -$699.50 K(-797.4%) |
| Mar 1997 | - | $100.30 K | $100.30 K |
FAQ
- What is Nymox Pharmaceutical annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Nymox Pharmaceutical?
- What is Nymox Pharmaceutical TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Nymox Pharmaceutical?
What is Nymox Pharmaceutical annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of NYMX is -$6.28 M
What is the all time high annual EBITDA for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high annual earnings before interest, taxes, depreciation & amortization is -$2.81 M
What is Nymox Pharmaceutical quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of NYMX is -$1.33 M
What is the all time high quarterly EBITDA for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.87 M
What is Nymox Pharmaceutical TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of NYMX is -$2.59 M
What is the all time high TTM EBITDA for Nymox Pharmaceutical?
Nymox Pharmaceutical all-time high TTM earnings before interest, taxes, depreciation & amortization is $100.30 K